Journal of Pain & Palliative Care Pharmacotherapy最新文献_第3页

In the End, What Shall We Say? 最后，我们该说什么？

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-31 DOI: 10.1080/15360288.2026.2673911

Zhaohui Su

引用次数: 0

Pharmacological Interventions for Anxiety and Depression in Terminal Illness: A Scoping Review of Randomized Controlled Trials. 晚期疾病患者焦虑和抑郁的药物干预：随机对照试验的范围综述。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-20 DOI: 10.1080/15360288.2026.2669182

Orlin Chowdhury, Kristen Kyone, Craig Goldie, Aynharan Sinnarajah, Jean Mathews

{"title":"Pharmacological Interventions for Anxiety and Depression in Terminal Illness: A Scoping Review of Randomized Controlled Trials.","authors":"Orlin Chowdhury, Kristen Kyone, Craig Goldie, Aynharan Sinnarajah, Jean Mathews","doi":"10.1080/15360288.2026.2669182","DOIUrl":"10.1080/15360288.2026.2669182","url":null,"abstract":"Anxiety and depression are highly prevalent among patients with chronic and progressive illnesses. At the terminal stage, these symptoms are closely linked with existential distress and can worsen quality of life. A scoping review of randomized controlled trials (RCTs) reporting on pharmacological interventions for anxiety and depression in terminal illnesses was conducted. MEDLINE, Embase, and CENTRAL databases were searched from inception to September 2024. Two reviewers independently extracted data on study design, population, interventions, and outcomes. Thirteen RCTs involving 621 participants were included. Eight studies included patients with advanced cancer, two included patients with end-stage renal disease, two included patients with advanced Human Immunodeficiency Virus, and one included patients with severe Chronic Obstructive Pulmonary Disease. The most studied drug classes were selective serotonin reuptake inhibitors and psychostimulants (5 of each). Overall, 10 of 13 studies reported statistically significant improvement in depression or anxiety. Pharmacological interventions improved depression and anxiety in terminal illness. Larger RCTs in non-cancer populations, particularly advanced heart disease, cerebrovascular disease, and dementia, which represent leading causes of morbidity and mortality globally, are needed. Studies should include drug classes commonly used in clinical practice such as noradrenaline and specific serotonergic antidepressants, serotonin-norepinephrine reuptake inhibitors, and benzodiazepines.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"524-535"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort. 患有神经性疼痛的癌症患者：药剂师主导的推荐和管理以及单中心回顾性观察队列中的米罗巴林结果。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-06-12 DOI: 10.1080/15360288.2026.2684413

Shinya Kajiura, Yudai Ishikawa, Atsushi Kato, Ryuji Hayashi

{"title":"Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort.","authors":"Shinya Kajiura, Yudai Ishikawa, Atsushi Kato, Ryuji Hayashi","doi":"10.1080/15360288.2026.2684413","DOIUrl":"10.1080/15360288.2026.2684413","url":null,"abstract":"This single-center retrospective cohort study assessed whether pharmacist-led recommendation and management was associated with effectiveness and safety outcomes of mirogabalin for cancer-related neuropathic pain. Among 143 patients prescribed mirogabalin, 85 adults with malignancy were included. Patients were classified into a pharmacist-led recommendation and management group (n = 18), in which a board-certified oncology pharmacist recommended mirogabalin and supported subsequent prescribing, or a usual-care-without-pharmacist-recommendation group (n = 67), in which mirogabalin was prescribed without a pharmacist-led recommendation. The primary endpoint was recorded subjective effectiveness, defined as documented pain relief or symptom improvement in the electronic health record; the per-protocol analysis excluded non-evaluable records, leaving denominators of 13 and 52, respectively. Recorded subjective effectiveness was 13/13 (100.0%) in the pharmacist-led recommendation group versus 36/52 (69.2%) in the usual-care-without-pharmacist-recommendation group (p = 0.027). In an ITT-like conservative sensitivity analysis, the direction of association was consistent but not statistically significant (13/18 [72.2%] vs 36/67 [53.7%]; p = 0.188). AE-related discontinuation occurred in 1/18 (5.6%) patients in the pharmacist-led recommendation group versus 8/67 (11.9%) patients in the usual-care-without-pharmacist-recommendation group (p = 0.677). Pharmacist-led recommendation and management was associated with higher recorded subjective effectiveness of mirogabalin in the per-protocol analysis. These findings are hypothesis-generating and support prospective evaluation of pharmacist-supported mirogabalin initiation in cancer-related neuropathic pain.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"425-432"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148226166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subcutaneous Administration of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Pain Management: A Systematic Review and Meta-Analysis. 非甾体抗炎药（NSAIDs）皮下注射治疗疼痛：系统回顾和荟萃分析。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 DOI: 10.1080/15360288.2026.2725819

Moeko Omiya, Toshihiko Takada, Honami Yoshida, Yuki Kanno, Ryuji Suzuki, Jun Miyashita

{"title":"Subcutaneous Administration of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Pain Management: A Systematic Review and Meta-Analysis.","authors":"Moeko Omiya, Toshihiko Takada, Honami Yoshida, Yuki Kanno, Ryuji Suzuki, Jun Miyashita","doi":"10.1080/15360288.2026.2725819","DOIUrl":"https://doi.org/10.1080/15360288.2026.2725819","url":null,"abstract":"This review aimed to evaluate the efficacy and safety of subcutaneous nonsteroidal anti-inflammatory drugs (NSAIDs).We searched CENTRAL, MEDLINE, Embase, trial registries, and Google Scholar until December 19, 2024. Eligible studies were randomized controlled trials (RCTs) in adults comparing subcutaneous NSAIDs with other routes of administration, placebo, no treatment, or other drugs. The primary outcome was pain intensity; secondary outcomes were rescue medication use and adverse events. We assessed risk of bias using the Risk of Bias 2 tool. Random-effects meta-analyses used standardized mean differences (SMDs) for pain intensity and odds ratios for rescue medication use. Adverse events were summarized narratively.Four RCTs (n = 825) were included: three placebo-controlled trials and one route-comparison trial, all evaluating short-term treatment for acute pain with subcutaneous diclofenac or ketorolac. In the meta-analysis of three placebo-controlled trials (n = 500), subcutaneous NSAIDs reduced pain (SMD = 0.72; 95% CI, 0.22 to 1.21; I2 = 82.8%) and rescue medication use. Adverse-event data were limited and inconsistent, with one trial reporting higher event rates with subcutaneous NSAIDs than placebo and another reporting comparable rates. The route-comparison trial showed comparable efficacy and safety between subcutaneous and intramuscular diclofenac.In conclusion, subcutaneous diclofenac and ketorolac may reduce short-term acute pain compared with placebo. However, the evidence is limited and safety remains uncertain. Further route-comparison studies are needed.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-Effectiveness of Integrative Pain Management for Chronic Pain: A Systematic Review of Economic Evaluation. 慢性疼痛综合治疗的成本效益：经济评估的系统回顾。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-06-08 DOI: 10.1080/15360288.2026.2678983

Yuriz Bakhtiar, Arlina Dewi, Rafi Ilmansyah

{"title":"Cost-Effectiveness of Integrative Pain Management for Chronic Pain: A Systematic Review of Economic Evaluation.","authors":"Yuriz Bakhtiar, Arlina Dewi, Rafi Ilmansyah","doi":"10.1080/15360288.2026.2678983","DOIUrl":"10.1080/15360288.2026.2678983","url":null,"abstract":"Chronic pain significantly impacts quality of life and productivity, with Integrative Pain Management (IPM) offering a potential solution. However, its cost-effectiveness compared to usual care remains unclear. This systematic review assesses the economic evaluations of IPM interventions for chronic pain. Seven randomized controlled trials (RCTs) were included, focusing on cost-effectiveness measures such as the Incremental Cost-Effectiveness Ratio (ICER) and quality-adjusted life years (QALYs). The results showed a broad range of ICER values, from $2,808 to $74,868 per QALY, depending on the intervention type and perspective. QALY gains ranged from 0.009 to 0.09, with certain studies indicating favorable cost-effectiveness for integrated care programs for chronic low back pain. However, some higher-cost interventions demonstrated limited or unfavorable cost-effectiveness, highlighting the variability in economic outcomes based on the intervention design and target population. These findings underscore the need for comprehensive economic evaluations that account for both direct and indirect costs, including productivity losses. Integrated care for chronic low back pain and multidisciplinary interventions such as cognitive behavioral therapy appear promising. Policymakers should prioritize long-term economic assessments to guide healthcare decision-making across diverse chronic pain conditions.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"474-488"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Buprenorphine Initiation Regimen for Pain in Two Pregnant Patients with Sickle Cell Disease. 丁丙诺啡起始方案治疗2例妊娠镰状细胞病患者的疼痛。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-06 DOI: 10.1080/15360288.2026.2663401

Sharon Jia, Sarah Minor, Jennifer Hardcopf Stagg

{"title":"Buprenorphine Initiation Regimen for Pain in Two Pregnant Patients with Sickle Cell Disease.","authors":"Sharon Jia, Sarah Minor, Jennifer Hardcopf Stagg","doi":"10.1080/15360288.2026.2663401","DOIUrl":"10.1080/15360288.2026.2663401","url":null,"abstract":"Sickle cell disease (SCD) causes significant morbidity and mortality, affecting approximately 100,000 people in the United States. Chronic pain negatively impacts quality of life and is estimated to occur in 30% to 40% of adolescents and adults with SCD. As a result, patients often rely on opioids for pain control. Management of pain and opioid use is further complicated when patients with SCD become pregnant. Patients with SCD face an increased risk of maternal and perinatal complications compared to the nonpregnant sickle cell population. In the SCD population, buprenorphine is thought to be a safer alternative than full mu opioid agonists like oxycodone. However, there is scant literature on the use of buprenorphine for pain in SCD patients who become pregnant. We present buprenorphine initiation for pain in two pregnant patients with SCD on chronic opioids. The buprenorphine transition was started by the inpatient palliative care team and continued by the outpatient palliative providers. As the patients' pregnancies progressed, we encountered challenges with continuing buprenorphine for pain in SCD. Neither patient remained on buprenorphine for the full duration of their pregnancy. We describe the challenges and lessons we learned in these cases.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"549-557"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and Factors Associated with Receiving a Prescription for a Direct Oral Anticoagulant Among Patients with Atrial Fibrillation on Hospice Admission. 在临终关怀住院的房颤患者中接受直接口服抗凝剂处方的患病率和相关因素。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 DOI: 10.1080/15360288.2026.2724958

Phuong Y Duong, Emily K Short, Jennifer Tjia, Matthew Alcusky, Mary Lynn McPherson, Jon P Furuno

{"title":"Prevalence and Factors Associated with Receiving a Prescription for a Direct Oral Anticoagulant Among Patients with Atrial Fibrillation on Hospice Admission.","authors":"Phuong Y Duong, Emily K Short, Jennifer Tjia, Matthew Alcusky, Mary Lynn McPherson, Jon P Furuno","doi":"10.1080/15360288.2026.2724958","DOIUrl":"https://doi.org/10.1080/15360288.2026.2724958","url":null,"abstract":"Atrial fibrillation (AF) is prevalent in hospice care, but anticoagulation decisions in this population are not well understood. In this cross-sectional study, we described the prevalence and characteristics associated with direct oral anticoagulant (DOAC) prescription on hospice admission. We used electronic health data from adult decedents with AF in a large, for-profit hospice chain in the United States between January 1, 2017 and December 31, 2019. We used multivariable logistic regression with results reported as adjusted odds ratios (AORs) and 95% confidence intervals (CIs). Among 13,233 decedents, mean (standard deviation [SD]) age was 84.2 (9.9) years, 53.6% were female, 65.1% were White, and 56.1% were referred to hospice from a hospital. Mean (SD) CHA2DS2-VASc score were 3.8 (1.4) for males and 4.8 (1.3) for females, and mean (SD) HAS-BLED score was 2.2 (1.0). Overall, 8% of patients received a DOAC prescription on hospice admission. Characteristics associated with receiving a DOAC prescription included PPS scores of ≥ 20% (compared to scores < 20%), and receiving hospice care at home, nursing home, assisted living facility, or residential care home (compared to inpatient hospice). Further studies about the risks and benefits of DOAC use are needed to optimize decision-making in this population.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Price of Goodbye. 告别的代价。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-31 DOI: 10.1080/15360288.2026.2673912

Zhaohui Su

引用次数: 0

Integrating Non-Pharmacological Approaches in Chronic Pain Management: The Role of Healthcare Provider Education. 整合非药物方法在慢性疼痛管理：医疗保健提供者教育的作用。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-22 DOI: 10.1080/15360288.2026.2676628

Haleema Sadia, Fatima Rafique

引用次数: 0

Systemic Amyloidosis: A Clinical Challenge from the Palliative Care Perspective. 系统性淀粉样变：从姑息治疗角度的临床挑战。

IF 1.3

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-07-06 DOI: 10.1080/15360288.2026.2695622

John Lidemberto Cárdenas Cárdenas, Verónica Elena Páez Avendaño, Fabián Andrés Charry Monsalve

{"title":"Systemic Amyloidosis: A Clinical Challenge from the Palliative Care Perspective.","authors":"John Lidemberto Cárdenas Cárdenas, Verónica Elena Páez Avendaño, Fabián Andrés Charry Monsalve","doi":"10.1080/15360288.2026.2695622","DOIUrl":"10.1080/15360288.2026.2695622","url":null,"abstract":"Amyloidosis is a rare disease characterized by the extracellular deposition of misfolded amyloid proteins in various organs and tissues, leading to progressive organ dysfunction. Due to the complexity of its management, the high symptom burden it generates, and the difficulty in determining prognosis, palliative care plays a fundamental role in comprehensive management and in improving patients' quality of life. This article presents a narrative review aimed at examining the available evidence on palliative interventions in patients with amyloidosis for symptom control, psychosocial support, and shared decision-making. The findings suggest that a patient-centered interdisciplinary approach enables more effective management of pain, dyspnea, fatigue, and other associated symptoms, in addition to enhancing emotional well-being and facilitating advance care planning. The importance of early assessment of palliative care needs and the integration of specialized teams from the initial stages of diagnosis is emphasized, in order to optimize symptom management and provide comprehensive support to patients and their families. Despite progress, gaps remain in the literature regarding specific palliative care interventions and their long-term impact, highlighting the need for further research in this field.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"536-548"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0